Subsequently, the same group evaluated the combined effect of adecatumumab with Docetaxel (DTX) in a phase IB trial in 31 women with advanced-stage BC, especially for high EpCAM-expressing tumors. The gene discussed is EPCAM; the disease is breast cancer.